Pronota has developed an integrated process for the discovery and rapid validation of high-value, low abundance protein biomarkers from complex biological samples including plasma. The technology is being applied to in-house and partnered programs to develop novel protein diagnostics and therapeutics.
 

Speaker Profile

Nick McCooke, CEO

Nick McCooke is CEO of Pronota NV. He was previously CEO of Solexa, the developer of ultra-throughput DNA sequencing technology, which he took from university spinout in 2000 to the reverse takeover of a NASDAQ listed company in 2005. During that period, he raised nearly $40M in venture capital funding. The company was acquired by Illumina in 2007 for $600 million and is the dominant player in the next generation sequencing market. Previously he was President of Rapigene Inc, Seattle, USA, one of the first wave of SNP genotyping companies, which he sold to Qiagen NV at the end of 1999. Prior to this he held several general management roles in Innovex (now part of Quintiles Inc). These included the green-field start-up of a pharma contract sales organization (CSO) in Japan. As a member of the Innovex core general management team he contributed to the value creation that led to its trade sale to Quintiles for around $800 million. He began his biotech career with Celltech where he held a number of commercial management positions. He holds BSc and MSc degrees in engineering and an MBA from the London Business School.